Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**2',3'-Dideoxyadenosine triphosphate (ddATP)** is a synthetic purine nucleoside triphosphate analog in which the ribose moiety lacks hydroxyl groups at both the 2' and 3' positions. This modification prevents further chain elongation when incorporated into DNA or RNA by polymerases, making ddATP a potent inhibitor of DNA polymerases and reverse transcriptases. It is primarily used as a biochemical tool in molecular biology for Sanger sequencing and as an active metabolite of certain antiretroviral drugs such as didanosine (ddI). ddATP itself is not approved for therapeutic use but plays an important role in research settings[1][7][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2',3'-dideoxyadenosine triphosphate.